酒石酸二氢可待因控释片对晚期癌痛病人镇痛效果临床评价

CLINICAL EVALUATION OF ANALGESIC EFFECT OF DIHYDROCODEINE TARTRATE CONTROLLED RELEASE TABLETS IN CANCER PAIN

应用酒石酸二氢可待因控释片（简称控释片）与酒石酸二氢可待因普通片（简称普通片）随机双盲对照试验，对晚期癌症伴有中、重度疼痛的患者进行镇痛效果及不良反应观察。结果表明：控释片每１２ｈ口服一次可以有效控制晚期癌症慢性中度以上疼痛。与普通片相比较，镇痛效果在日剂量相同的情况下，组间差异无显著性。控释片的不良反应主要有头晕、恶心、呕吐等，与普通片相比。

A randomized and double-blind clinical trial of the analgesic effect of dihydrocodeine tartrate controlled release tablets (CDHC) was carried out on cancer patients in terminal state with moderate and severe pain. Dihydrocodeine tartrate immediate-release tablets (IDHC) was used as positive control. Results indicated that CDHC was effective in the control of moderate to severe cancer-related pain while administered every 12 hours, there was no significant difference between CDHC and IDHC. The adverse drug reactions of CDHC and IDHC showed the same profile, they were dizziness, nausea and vomiting .